Loading clinical trials...
Loading clinical trials...
A Phase III, Randomized, Double-Blind. Placebo-Controlled, Multi-Center Study of Systemic Lupus Erythematosus With Acute Severe SLE Flares Excluding Renal or Neurological Systems
The purpose of the study is to evaluate the safety \& efficacy of Epratuzumab with standard treatments for patients with SLE.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Birmingham, Alabama, United States
Tucson, Arizona, United States
Los Angeles, California, United States
Upland, California, United States
Denver, Colorado, United States
Washington D.C., District of Columbia, United States
Baltimore, Maryland, United States
New York, New York, United States
The Bronx, New York, United States
Durham, North Carolina, United States
Start Date
June 1, 2005
Primary Completion Date
March 1, 2007
Completion Date
March 1, 2007
Last Updated
November 8, 2011
510
Estimated participants
epratuzumab
DRUG
Lead Sponsor
UCB Pharma
NCT06647069
NCT07371468
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT06333483